Sandoz Launches First And Only Biosimilar For Multiple Sclerosis, Tyruko® In Germany
Portfolio Pulse from Benzinga Newsdesk
Sandoz, a global leader in generic and biosimilar medicines, has launched Tyruko (natalizumab), the first and only biosimilar for treating relapsing-remitting multiple sclerosis (RRMS) in Germany as of February 1. Tyruko, developed by Polpharma Biologics, is indicated as a single disease-modifying therapy in adults with highly active RRMS, mirroring the indication of the reference medicine Tysabri. Rebecca Guntern, President Europe of Sandoz, emphasized the importance of early treatment with DMTs for MS patients and the role of Tyruko in enhancing access to effective therapies in Europe.
January 31, 2024 | 7:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sandoz's launch of Tyruko, the first biosimilar for RRMS in Germany, could lead to increased market share and revenues in the European biosimilar market.
The launch of Tyruko by Sandoz is a significant event as it is the first biosimilar for RRMS in the market, which could lead to a competitive advantage and potential growth in revenue for Sandoz. Given the importance of biosimilars in reducing healthcare costs and increasing access to treatment, this launch is likely to be viewed positively by investors and could have a favorable impact on Sandoz's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100